Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

41.39 +0.53 (+1.30%)
Streaming Delayed Price Updated: 2:41 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 517,288
Open 41.10
Bid (Size) 41.36 (2)
Ask (Size) 41.42 (4)
Prev. Close 40.86
Today's Range 40.87 - 41.66
52wk Range 29.85 - 45.00
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings For Halozyme Therapeutics
Via Benzinga
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. 
Via Investor's Business Daily

Performance

YTD
+10.70%
+10.70%
1 Month
+3.71%
+3.71%
3 Month
+22.89%
+22.89%
6 Month
+17.39%
+17.39%
1 Year
+36.69%
+36.69%

More News

Read More
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
Via Chartmill
Sarepta Therapeutics Stock Shows Improved Technical Strength
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Via InvestorPlace
NASDAQ:HALO is not too expensive for the growth it is showing.
Via Chartmill
9 Analysts Have This To Say About Halozyme Therapeutics
Via Benzinga
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
Via Chartmill
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
Via Chartmill
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Via Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
Via InvestorPlace
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:HALO, a strong growth stock, setting up for a breakout.
Via Chartmill
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
Via Benzinga
Halozyme Therapeutics: Q4 Earnings Insights
Via Benzinga
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Via InvestorPlace
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Earnings Preview: Halozyme Therapeutics
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
Via Chartmill
Gates Ventures, Mayo Clinic Back Tiny Robot Created By $400M Apple Face ID Inventors To Treat Brain Disease
Via Benzinga
NASDAQ:HALO, an undervalued stock with good fundamentals.
Via Chartmill
Earnings Scheduled For February 20, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.